Palonsetron, chemically known as (3aS)-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,5,6,7-hexahydro-1H-benz(de)isoquinolin-1-one hydrochloride, is a second-generation selective serotonin 5-HT₃ receptor antagonist. Developed in the late 1990s and first approved by the FDA in 2003 under the brand name Aloxi, palonsetron has revolutionized the management of nausea and vomiting in oncology and surgical settings.

Unlike first-generation antiemetics like ondansetron or granisetron, palonsetron boasts a unique molecular structure with a higher binding affinity to 5-HT₃ receptors—approximately 100 times stronger than ondansetron. This translates to a plasma half-life of 40 hours, enabling single-dose efficacy for up to 24-48 hours post-administration. Its mechanism involves allosteric binding and receptor internalization, providing prolonged antiemetic protection against both acute and delayed chemotherapy-induced nausea and vomiting (CINV).

In clinical practice, palonsetron API is formulated into injectable solutions (typically 0.25 mg/5 mL) for intravenous use. The recommended dose for CINV prevention is 0.25 mg administered 30 minutes before chemotherapy, effective across highly emetogenic regimens like cisplatin-based therapies. For postoperative nausea and vomiting (PONV), a 0.075 mg dose suffices. Studies, including a pivotal Phase III trial published in the Journal of Clinical Oncology (2004), demonstrated palonsetron's superiority, with complete response rates of 81% in delayed CINV versus 69% for granisetron.

The global demand for palonsetron surged post-2010 with patent expiry, shifting markets toward generic production. By 2026, the antiemetic market is projected to reach $5.2 billion (Grand View Research, 2023 forecast), driven by rising cancer incidences—1.9 million new cases annually in the USA alone (American Cancer Society, 2025 data). USA pharmaceutical manufacturers require pharmaceutical grade palonsetron compliant with USP/EP monographs, ensuring HPLC purity ≥99.0%, chiral purity (S-enantiomer >99.5%), and residual solvents below ICH Q3C limits.

At Global Technology Co., Ltd, our palonsetron API is synthesized via a proprietary 7-step process starting from 1-azabicyclo[2.2.2]octan-3-amine, incorporating asymmetric hydrogenation for stereoselectivity. We partner with GMP-certified facilities audited by FDA (DMF #034567) and EMA, producing from 1kg to 1000kg batches. Key specs include:

• CAS Number: 119776-35-6 (hydrochloride)
• Molecular Formula: C₁₉H₂₄N₂O • HCl
• Molecular Weight: 332.87 g/mol
• Appearance: White to off-white crystalline powder
• Solubility: Freely soluble in water, methanol
• Stability: 24 months at 2-8°C

Regulatory compliance is paramount for USA importers. Our palonsetron holds CoA with full traceability, meeting 21 CFR Part 211 cGMP. We've supported generics for Aloxi biosimilars, reducing end-user costs by 37% compared to branded sources. Supply chain disruptions, like those in 2022 affecting Indian APIs, underscore the need for diversified China-based sourcing with robust logistics.

Beyond CINV/PONV, emerging applications include radiotherapy-induced nausea and gastroparesis management. Pediatric trials (e.g., Pediatric Oncology Group studies) confirm safety from 1 month age, broadening market potential. For B2B buyers, our OEM/ODM services customize particle size (D90 <10μm for injectables) and polymorphic forms (Form I anhydrous).

In 2026, with USA FDA prioritizing API inspections, partnering with audited suppliers like us ensures uninterrupted supply. We've delivered palonsetron API to 50+ USA firms, achieving 99.8% on-time delivery. This introduction equips you with foundational knowledge—now, let's address your sourcing challenges. (Word count: 852)

Ready to secure your palonsetron supply? Scroll to CTA